Sugi Predict

Sugi Predict / Compounds / SCHEMBL752806

SCHEMBL752806

SCHEMBL752806

COC(=O)c1cc(Cl)c(O)c([N+](=O)[O-])c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR35 Q9HC97 2/20 0.54
▸ MAPT P10636 4/20 0.51
▸ POLB P06746 3/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ RXFP1 Q9HBX9 1/20 0.51
▸ LMNA P02545 4/20 0.50
▸ ERN1 O75460 2/20 0.50
▸ VCAM1 P19320 1/20 0.50
▸ KDM4E B2RXH2 2/20 0.49
▸ MAPK1 P28482 2/20 0.48
▸ ESR1 P03372 1/20 0.48
▸ GFER P55789 2/20 0.47
▸ GAA P10253 1/20 0.47
▸ NFKB1 P19838 1/20 0.47
▸ XDH P47989 1/20 0.47
▸ NFKB2 Q00653 1/20 0.47
▸ RELA Q04206 1/20 0.47
▸ FUT7 Q11130 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29621637 1.00 GPR35 (0.54) GPR35MAPTPOLBMEN1KMT2A
SCHEMBL5924211 0.89 ESR1 (0.57) GPR35MAPTPOLBMEN1KMT2A
Hydrochloric Acid SCHEMBL9064842 0.87 ESR1 (0.56) GPR35MAPTPOLBMEN1KMT2A
SCHEMBL22081923 0.86 MAPT (0.52) MAPTPOLBMEN1KMT2ARXFP1
SCHEMBL30159180 0.86 MAPT (0.52) MAPTPOLBMEN1KMT2ARXFP1
SCHEMBL2809633 0.84 LMNA (0.53) MAPTPOLBMEN1KMT2ALMNA
SCHEMBL2903036 0.84 MAPT (0.51) MAPTPOLBMEN1KMT2ARXFP1
SCHEMBL643856 0.84 KDM4E (0.65) GPR35MAPTPOLBMEN1KMT2A
SCHEMBL31440703 0.84 KDM4E (0.65) GPR35MAPTPOLBMEN1KMT2A
SCHEMBL13011349 0.84 ESR1 (0.58) GPR35MAPTPOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361238-A1 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER SOPONPONG JAKAPUN (TH) 2025-11-27 — — US disclosed
US-20250325660-A1 IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE INCYTE CORP (US) 2025-10-23 — — US disclosed
EP-4566675-A2 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS Incyte Corporation (US) 2025-06-11 — — EP disclosed
US-20250171443-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2025-05-29 — — US disclosed
US-20250163038-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. 2025-05-22 — — US disclosed
CN-119613400-A Heterocyclic compounds as immunomodulators 因赛特公司 2025-03-14 — — CN disclosed
US-12247026-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2025-03-11 — — US disclosed
EP-4212529-B1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORP (US) 2025-01-29 — — EP disclosed
US-20240376106-A1 PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR INCYTE CORPORATION 2024-11-14 — — US disclosed
CN-112135824-B Heterocyclic compounds as immunomodulators 因赛特公司 2024-11-05 — — CN disclosed
WO-2007140982-A1 SUBSTITUTED BENZOXAZOLES BAYER HEALTHCARE AG (DE) 2007-12-13 — — WO disclosed
WO-2007140982-A1 SUBSTITUTED BENZOXAZOLES BAYER HEALTHCARE AG (DE) 2007-12-13 — — WO disclosed
WO-2007093507-A1 HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-23 — — WO disclosed
US-20070191603-A1 Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-08-16 — — US disclosed
EP-1293213-A1 PREVENTIVES/REMEDIES FOR POSTOPERATIVE STRESS JAPAN TOBACCO INC. (JP) 2003-03-19 — — EP disclosed
EP-0207454-B1 ISOXAZOLE AND FURAN DERIVATIVES, THEIR PREPARATION AND USE AS ANTIVIRAL AGENTS STERLING WINTHROP INC. (US) 1992-09-09 — — EP disclosed
US-5002960-A Viricides for combating picornaviruses STERLING DRUG, INC. (US) 1991-03-26 — — US disclosed
US-4939267-A Viricides STERLING DRUG INC. (US) 1990-07-03 — — US disclosed
US-4843087-A OXAZOLINYL COMPOUNDS; RHINOVIRUSES AND PICORNAVIRUSES STERLING DRUG INC. (US) 1989-06-27 — — US disclosed
EP-0207454-A2 Isoxazole and furan derivatives, their preparation and use as antiviral agents STERLING WINTHROP INC. (US) 1987-01-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325660-A1 IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE CD274, PDCD1LG2, PDCD1 GPR35 1209/4885MAPT 4007/4885POLB 4019/4885
US-20250163038-A1 CBL-B MODULATORS AND USES THEREOF CBLB, CBL, CBLC GPR35 4051/4885MAPT 4064/4885POLB 238/4885
US-20240376106-A1 PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR PDCD1, CD274, PDCD1LG2 GPR35 4658/4885MAPT 1677/4885POLB 248/4885
US-20250361238-A1 1,4-DIPHENYL-1H-INDAZOLE AND 1-PYRIDIN-2-YL-4-PHENYL-1H-INDAZOLE DERIVATIVES AS PD-1/PD-L1 MODULATORS FOR THE TREATMENT OF CANCER PDCD1, CD274, PDCD1LG2 GPR35 1881/4885MAPT 3003/4885POLB 1793/4885
US-12247026-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS GPR35 648/4885MAPT 4651/4885POLB 3038/4885
US-20070191603-A1 Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors CPT1A, CPT1B, CPT2 GPR35 2663/4885MAPT 3162/4885POLB 1620/4885
US-20250171443-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS GPR35 648/4885MAPT 4651/4885POLB 3038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.